Hidradenitis Suppurativa Clinician-Patient Summit
Hidradenitis suppurativa has significant impacts on patients’ quality of life, however, it remains underdiagnosed, misdiagnosed, or incorrectly treated.  Until recently, there was a scarcity of evidence about long-term management strategies and no evidence-based consensus guidelines.  The updated
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 Participation
Advances in Managing Eosinophilic Esophagitis: Tips for the Practicing Clinician
Eosinophilic esophagitis (EoE), a chronic, debilitating illness that is mediated via cells of the immune system (eosinophils) eliciting T-helper 2 (Th2) cell mediated inflammation, affects several people globally and imparts significant impact on the quality of life (QoL) o
Category
  • TME
Format
  • Self-study / Enduring
  • Webinar recorded
Credits
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
AhR Agonists for Psoriasis: A Novel Mechanism for Treatment of PsO
Psoriasis is a difficult disease to manage due to a variety of factors including fluctuations in disease severity, limited treatment options, and a limited understanding of the pathogenesis of disease.
Category
  • LivDerm
  • TME
Format
  • Self-study / Enduring
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis.
Category
  • CMHC
  • TME
Format
  • Self-study / Enduring
Credits
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
  • 0.75 Participation
According to the Patient: Alopecia Areata in Adolescence
The management of AA in adolescents presents various challenges to dermatology professionals, including identification of AA, limited effective treatment options, and high disease burden.
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Expanding the Therapeutic “AHR”senal for Pediatric Atopic Dermatitis
Aryl hydrocarbon receptor (AhR) agonist therapy for pediatric atopic dermatitis (AD) has shown much promise for addressing current treatment challenges with 1) efficacy in reducing atopic lesions and itching, 2) a rapid onset of action, and 3) improvement in quality of life without the safety con
Category
  • LivDerm
  • TME
Format
  • Video
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation